Glucagon-like peptide-1 — commonly referred to as GLP-1 — is a peptide hormone produced in the gut in response to food intake. It belongs to the incretin family of hormones, a group of gut-derived signals that enhance insulin secretion after meals. Despite being a relatively short peptide (30 amino acids in its active form), GLP-1 has an extraordinarily broad influence on metabolism, appetite regulation, gastric function, and even neurobiology.
Understanding what GLP-1 is and how it works is essential context for anyone researching GLP-1 receptor agonist peptides, whether for scientific interest or personal exploration. This guide covers the biology from first principles.
Where GLP-1 Comes From
GLP-1 is produced primarily by L-cells — specialised enteroendocrine cells found in the lining of the distal small intestine and colon. When nutrients pass through the gut, particularly fats and carbohydrates, L-cells are triggered to release GLP-1 into the bloodstream.
What makes GLP-1’s origin biochemically interesting is that it comes from the same precursor gene as glucagon — the proglucagon gene. In the pancreatic alpha cells, proglucagon is processed to produce glucagon, a hormone that raises blood glucose. In the intestinal L-cells, the same precursor is processed differently by a different enzyme (prohormone convertase 1/3 rather than PC2), yielding GLP-1 and GLP-2 instead.
This means two hormones with almost opposite metabolic effects — glucagon (raises glucose) and GLP-1 (lowers glucose indirectly) — come from the same gene, just read differently in different tissues. This is one of the more elegant examples of tissue-specific gene processing in human biology.
GLP-1 is also produced in smaller quantities by specific neurons in the brainstem, particularly in the nucleus tractus solitarius. This central GLP-1 functions as a neuropeptide and is distinct from the peripheral GLP-1 released by the gut — though both activate the same receptor.
The GLP-1 Receptor
GLP-1 exerts its effects by binding to the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor (GPCR). Class B GPCRs are characterised by a large extracellular domain at their N-terminus that participates directly in ligand recognition — structurally distinct from the class A GPCRs that make up the majority of drug targets.
The GLP-1R is expressed in multiple tissues, which explains why GLP-1 has such a diverse range of effects beyond the pancreas. Key sites of expression include:
| Parameter | Detail |
| Pancreatic beta cells | Primary insulin-secreting cells; GLP-1R activation enhances glucose-stimulated insulin secretion |
| Pancreatic alpha cells | GLP-1R activation suppresses glucagon secretion in a glucose-dependent manner |
| Hypothalamus | Key hunger-regulating region; GLP-1R activation reduces appetite signalling |
| Brainstem (area postrema) | Involved in satiety and nausea; highly sensitive to GLP-1R agonists |
| Stomach | Slows gastric emptying via GLP-1R activation on vagal nerve terminals |
| Heart and vasculature | Cardiomyocytes and vascular endothelium express GLP-1R; subject of ongoing cardiovascular research |
| Kidney | Renal tubular cells express GLP-1R; influences sodium excretion in research models |
The Incretin Mechanism: How GLP-1 Controls Insulin
The incretin effect refers to the observation that oral glucose produces a substantially greater insulin response than the same amount of glucose delivered intravenously. This difference — roughly 50–70% of the total insulin response after an oral meal — is attributable to incretin hormones, primarily GLP-1 and GIP (glucose-dependent insulinotropic polypeptide).
GLP-1 amplifies insulin secretion through the following mechanism: after binding to GLP-1R on pancreatic beta cells, the receptor activates the Gs protein, which stimulates adenylyl cyclase to produce cyclic AMP (cAMP). Rising cAMP activates protein kinase A (PKA) and Epac2 (exchange protein directly activated by cAMP), both of which enhance the insulin secretion machinery.
Critically, this amplification is glucose-dependent. GLP-1 only enhances insulin secretion when blood glucose is elevated above fasting levels. At normal fasting glucose concentrations, GLP-1R stimulation has minimal effect on insulin output. This glucose dependency is one of the most pharmacologically attractive properties of the GLP-1 system — it means GLP-1 receptor agonists carry a very low risk of causing hypoglycaemia, unlike some other insulin secretagogues.
Beyond Insulin: The Full Range of GLP-1 Effects
While the incretin function is the most studied aspect of GLP-1 biology, it is far from the only one. Research has characterised a wide range of additional effects:
Glucagon Suppression
GLP-1 suppresses glucagon secretion from pancreatic alpha cells in a glucose-dependent manner. Since glucagon signals the liver to release stored glucose (glycogenolysis) and synthesise new glucose (gluconeogenesis), reducing postprandial glucagon helps keep blood glucose levels lower after meals.
Gastric Emptying
GLP-1R activation slows the rate at which the stomach empties food into the small intestine. This has two consequences: it reduces the speed of postprandial glucose absorption (smoothing the glucose curve after eating), and it contributes to feelings of fullness by prolonging the physical presence of food in the stomach.
Appetite and Satiety
GLP-1 signals to the brain through multiple pathways. Peripherally released GLP-1 activates vagal afferent nerves that carry satiety signals to the brainstem. Centrally, GLP-1 produced in the brainstem and circulating GLP-1 that crosses the blood-brain barrier act on hypothalamic nuclei involved in hunger regulation, particularly the arcuate nucleus and the paraventricular nucleus.
The net result is reduced appetite, earlier satiety during meals, and reduced food-seeking behaviour. This central effect is one reason GLP-1 receptor agonists produce more significant reductions in food intake than would be predicted from their peripheral metabolic effects alone.
Beta Cell Preservation
In animal research, GLP-1 has been shown to promote beta cell proliferation, reduce beta cell apoptosis (programmed cell death), and enhance beta cell differentiation from progenitor cells. Whether similar effects occur in humans at physiological or pharmacological GLP-1 concentrations remains an active area of clinical research.
Why Native GLP-1 Has a Very Short Half-Life
Despite its broad biological importance, native GLP-1 has an extremely short circulating half-life — approximately 1–2 minutes in the bloodstream. This rapid degradation occurs through two main mechanisms.
First, the enzyme dipeptidyl peptidase-4 (DPP-4) cleaves GLP-1 at the second amino acid from its N-terminus (alanine at position 2), converting active GLP-1(7-36) amide into inactive GLP-1(9-36) amide. DPP-4 is expressed ubiquitously on the surface of endothelial cells throughout the vasculature, meaning GLP-1 encounters it almost immediately upon entering the bloodstream.
Second, renal filtration removes intact GLP-1 from circulation. The combination of these two processes means that the majority of GLP-1 released by the gut is inactivated before it even reaches the systemic circulation in its active form.
This short half-life is why synthetic GLP-1 receptor agonist peptides were developed with specific structural modifications to resist DPP-4 cleavage and extend their duration of action — enabling once-weekly dosing in some cases rather than the continuous infusion that native GLP-1 would require.
The Discovery of GLP-1
GLP-1 was identified in the mid-1980s as a product of the proglucagon gene. The key researchers who characterised its incretin function included Jens Juul Holst at the University of Copenhagen, Joel Habener at Massachusetts General Hospital, and Daniel Drucker at the University of Toronto. Their work through the late 1980s and 1990s established GLP-1 as the dominant incretin hormone and laid the scientific foundation for what has become one of the most clinically significant peptide research programmes in modern medicine.
Holst’s group in particular made foundational contributions to understanding how GLP-1 is secreted, degraded, and how its receptor functions — work that directly enabled the subsequent development of GLP-1 receptor agonist therapeutics.
GLP-1 Research Peptides vs Pharmaceutical GLP-1 Agonists
It is important to distinguish between GLP-1 receptor agonist peptides available for research purposes and pharmaceutical GLP-1 agonist medications. Pharmaceutical products (such as branded semaglutide medications) are approved drugs, manufactured under pharmaceutical GMP conditions, tested extensively in clinical trials, and prescribed by physicians for specific indications.
Research peptides are compounds supplied for laboratory and experimental use — to study GLP-1 receptor biology, examine dosing protocols in research contexts, or investigate the compound’s properties outside of the clinical setting. The purity standards, intended use, and regulatory context are entirely different.
This guide — and the broader content on this site — is written for informational purposes about the science and research context of GLP-1 biology, not as medical advice or a guide to pharmaceutical use.
ℹ️ This article is for educational and informational purposes only. It does not constitute medical advice. If you are considering any peptide compound for personal use, consult a qualified medical professional.